Compare · DXCM vs SKYA
DXCM vs SKYA
Side-by-side comparison of DexCom Inc. (DXCM) and SkyAI Inc. (SKYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SKYA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.62B, about 232.5x SKYA ($127.4M).
- DXCM has been more active in the news (8 items in the past 4 weeks vs 6 for SKYA).
- DXCM has more recent analyst coverage (25 ratings vs 0 for SKYA).
- Company
- DexCom Inc.
- SkyAI Inc.
- Price
- -
- -
- Market cap
- $29.62B
- $127.4M
- 1M return
- -5.96%
- -
- 1Y return
- +44.81%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
SkyAI Inc.
SkyAI, Inc. (Nasdaq: SKYA) is an artificial intelligence company building an agentic finance platform for the Global South. The Company uses AI to deliver financial access, education and actionable intelligence globally.
Latest DXCM
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
- Dexcom Reports Third Quarter 2026 Financial Results
- EVP Chief People & Culture Off Stern Sadie sold $201,660 worth of shares (2,565 units at $78.62) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
- EVP Chief Legal Compliance Off Brown Michael Jon sold $145,316 worth of shares (1,700 units at $85.48) as part of a pre-agreed trading plan (SEC Form 4)
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
Latest SKYA
- SkyAI Files Amended Tender Offer Documents and Reminds Security Holders To Tender Before the November 12, 2026 Expiration
- Bastion Trading Limited Reaches Agreement with SkyAI for Amendments to Tender Offer and Announces That It Will Tender All of Its SkyAI Securities
- SkyAI Enters into Tender Support and Settlement Agreement with Bastion Trading Limited; Extends Cash Tender Offer to All Pre-Funded Warrants and Includes All Stapled Warrants
- Third Eye Supports Bastion Trading's October 21 Call for Improved SkyAI Tender Terms
- Bastion Trading Calls on SkyAI Chairman and Directors to Demonstrate Accountability and to Provide a Better Tender Offer for All Stockholders and Pre-Funded Warrant Holders
- SkyAI Commences Cash Tender Offer to Purchase Up to 67.1 Million Shares and Warrants
- SkyAI to Commence $3.00 Per Share/Warrant Tender Offer and File Offer Materials with the SEC After Market Close on October 15, 2026
- Bastion Trading Challenges SkyAI’s Proposed Tender Offer, Demands Immediate and Full Disclosure of SOL Sales and Board Reconstitution
- SkyAI Announces Intention to Commence Cash Tender Offer to Purchase Common Stock and Pre-funded Warrants at $3.00 Per Share/Pre-funded Warrant
- Bastion Trading Calls on SkyAI to Respect Clear Stockholder Message by Promptly Engaging to Meaningfully Reconstitute the Board